Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Fleetwood, Filippa ^a   Klint, Susanne ^b   Hanze, Martin ^a   Gunneriusson, Elin ^b   Frejd, Fredrik Y ^b,c   Ståhl, Stefan ^a   Löfblom, John ^a  

^a ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^b Affibody AB   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMINOID; LIGAND; PEPTIDE LIBRARY; PROTEIN BINDING; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANIMAL; BINDING SITE; CELL LINE; HALF LIFE TIME; HEK293 CELL LINE; HUMAN; METABOLISM; MOUSE; PEPTIDE LIBRARY; PHYSIOLOGY;

ALBUMINS; ANIMALS; BINDING SITES; CELL LINE; HALF-LIFE; HEK293 CELLS; HUMANS; LIGANDS; MICE; PEPTIDE LIBRARY; PROTEIN BINDING; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84922784130     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07518     Document Type: Article

References (45)

1. Roskoski, R. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Critical reviews in oncology/hematology 62, 179-213, doi:10.1016/ j.critrevonc.2007.01.006 (2007).
2. Tugues, S., Koch, S., Gualandi, L., Li, X.&Claesson-Welsh, L. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol Aspects Med 32, 88-111, doi:10.1016/j.mam.2011.04.004 (2011).
3. Hanahan, D. &Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
4. Ferrara, N. Vascular endothelial growth factor: basic science and clinical progress. Endocrine reviews 25, 581-611 (2004).
5. Muller, Y. A. et al. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. P Natl Acad Sci USA 94, 7192-7197 (1997).
6. Brozzo, M. S. et al. Thermodynamic and structural description of allosterically regulated VEGFR-2 dimerization. Blood 119, 1781-1788, doi:10.1182/ blood2011-11-390922 (2012).
7. Matsui, J. et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14, 5459-5465, doi:10.1158/1078-0432.CCR-07-5270 (2008).
8. Polverino, A. et al.AMG706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 66, 8715-8721, doi:10.1158/0008-5472.CAN-05-4665 (2006).
9. Wilhelm, S.M. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64, 7099-7109, doi:10.1158/ 0008-5472.CAN-04-1443 (2004).
10. Mendel, D. B. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9, 327-337 (2003).
11. Sullivan, L. A. & Brekken, R. A. The VEGF family in cancer and antibody-based strategies for their inhibition. mAbs 2, 165-175 (2010).
12. He, K. et al. The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC). Onco Targets Ther 5, 59-65, doi:10.2147/OTT.S29719 (2012).
13. Potente, M., Gerhardt, H. & Carmeliet, P. Basic and therapeutic aspects of angiogenesis. Cell 146, 873-887, doi:10.1016/j.cell.2011.08.039 (2011).
14. Sessa, C., Guibal, A.,Del Conte, G. & Ruegg, C. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Clin Pract Oncol 5, 378-391, doi:10.1038/ncponc1150 (2008).
15. Lu, D. et al. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer 97, 393-399 (2002).
16. Lu, D. et al. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem 278, 43496-43507, doi:10.1074/ jbc.M307742200 (2003).
17. Gagner, J. P., Law, M., Fischer, I., Newcomb, E. W. & Zagzag, D. Angiogenesis in gliomas: imaging and experimental therapeutics. Brain Pathol 15, 342-363 (2005).
18. Price, S. J. & Gillard, J. H. Imaging biomarkers of brain tumour margin and tumour invasion. Br J Radiol 84 Spec No 2, S159-167, doi:10.1259/bjr/26838774 (2011).
19. Choe, Y. S. & Lee, K. H. Targeted in vivo imaging of angiogenesis: present status and perspectives. Curr Pharm Des 13, 17-31 (2007).
20. Olafsen, T. & Wu, A. M. Antibody vectors for imaging. Semin Nucl Med 40, 167-181, doi:10.1053/j.semnuclmed.2009.12.005 (2010).
21. Malm, M. et al. Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error- Prone PCR-Like Diversification. PLoS ONE 8, doi:DOI 10.1371/ journal.pone.0062791 (2013).
22. Orlova, A. et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 66, 4339-4348, doi:10.1158/0008-5472.CAN-05-3521 (2006).
23. Behdani, M. et al. Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth. New biotechnology 30, 205-209, doi:10.1016/j.nbt.2012.09.002 (2013).
24. Tolcher, A. W. et al. Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res 17, 363-371, doi:10.1158/1078-0432.CCR-10-1411 (2011).
25. Lofblom, J. et al. Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Letters 584, 2670-2680, doi:10.1016/j.febslet.2010.04.014 (2010).
26. Sorensen, J. et al. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 55, 730-735, doi:10.2967/jnumed.113.131243 (2014).
27. Wallberg, H. & Orlova, A. Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. Cancer Biother Radiopharm 23, 435-442, doi:10.1089/ cbr.2008.0464 (2008).
28. Orlova, A., Tran, T. A., Ekblad, T., Karlstrom, A. E. & Tolmachev, V. (186)RemaSGS- Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours. European journal of nuclear medicine and molecular imaging 37, 260-269, doi:10.1007/s00259-009-1268-9 (2010).
29. Wållberg, H., Ahlgren, S., Widström, C. & Orlova, A. Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys61]-Z HER2:2395(-Cys) affibody molecule for targeting of HER2-expressing tumors. Molecular imaging and biology: MIB: the official publication of the Academy of Molecular Imaging 12, 54-62, doi:10.1007/s11307-009-0238-8 (2010).
30. Tolmachev, V. et al. Imaging of EGFR expression in murine xenografts using sitespecifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected tracer amount. European journal of nuclear medicine and molecular imaging 37, 613-622, doi:10.1007/s00259-009-1283-x (2009).
31. Kronqvist, N., Lofblom, J., Jonsson, A., Wernerus, H. & Stahl, S. A novel affinity protein selection system based on staphylococcal cell surface display and flow cytometry. Protein Eng Des Sel 21, 247-255, doi:10.1093/protein/ gzm090 (2008).
32. Jonsson, A., Dogan, J., Herne, N., Abrahmsen, L. & Nygren, P. A. Engineering of a femtomolar affinity binding protein to human serum albumin. Protein Engineering Design and Selection 21, 515-527, doi:10.1093/protein/gzn028 (2008).
33. Kontermann, R. E. Strategies for extended serum half-life of protein therapeutics. Current Opinion in Biotechnology 22, 868-876, doi:10.1016/j.copbio.2011.06.012 (2011).
34. Orlova, A. et al. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 54, 961-968, doi:10.2967/jnumed.112.110700 (2013).
35. Olsson, A. K., Dimberg, A., Kreuger, J. & Claesson-Welsh, L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7, 359-371, doi:10.1038/nrm1911 (2006).
36. Kronqvist, N. et al. Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules. Protein EngDes Sel 24, 385-396, doi:10.1093/protein/gzq118 (2011).
37. Thiel, M. A. et al. Penetration of a topically administered anti-tumor necrosis factor alpha antibody fragment into the anterior chamber of the human eye. Ophthalmology 120, 1403-1408, doi:10.1016/j.ophtha.2012.12.015 (2013).
38. LaFleur, D. W. et al. Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides. mAbs 5, 208-218, doi:10.4161/mabs.23043 (2013).
39. Yu, F. et al. An affibody-adalimumab hybrid blocks combined IL-6 and TNFtriggered serum amyloid A secretion in vivo. mAbs 6 10.4161/mabs.36089 (2014).
40. Choi, H. J., Kim, Y. J., Lee, S. & Kim, Y. S. A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity. Mol Cancer Ther 12, 2748-2759, doi:10.1158/1535-7163.MCT-13-0628 (2013).
41. Shen, J. et al. Single variable domain-IgG fusion.Anovel recombinant approach to Fc domain-containing bispecific antibodies. J Biol Chem 281, 10706-10714, doi:10.1074/jbc.M513415200 (2006).
42. Papo,N., Silverman, A. P., Lahti, J. L.&Cochran, J. R. Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and avb3 integrin. P Natl Acad Sci USA 108, 14067-14072, doi:10.1073/pnas.1016635108/-/ DCSupplemental (2011).
43. Gronwall, C. et al. Selection and characterization of Affibody ligands binding to Alzheimer amyloid beta peptides. Journal of Biotechnology 128, 162-183, doi:10.1016/j.jbiotec.2006.09.013 (2007).
44. Lofblom, J., Kronqvist, N., Uhlén, M., Stahl, S. & Wernerus, H. Optimization of electroporation-mediated transformation: Staphylococcus carnosus as model organism. Journal of Applied Microbiology 102, 736-747, doi:10.1111/j.1365- 2672.2006.03127.x (2007).
45. Malm, M. et al. Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension. Biotechnology journal, doi:10.1002/biot.201400009 (2014).